Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,788.50
Bid: 1,788.50
Ask: 1,789.00
Change: 32.50 (1.85%)
Spread: 0.50 (0.028%)
Open: 1,743.50
High: 1,792.50
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-GoDaddy, Twitter, Pier 1, Michael Kors

Wed, 01st Apr 2015 16:27

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stocks dipped at the open on Wednesday as aweaker-than-expected report on private sector employment raisedconcerns that Friday's impending jobs report could also point toworsening conditions in the labor market.

The Dow Jones industrial average was down 0.60percent at 17,669.26, the S&P 500 was down 0.56 percentat 2,056.36 and the Nasdaq Composite was down 0.77percent at 4,862.98.

** GODADDY INC, $26.25, +31.25 pct

The web hosting company's shares rose as much as 34 percentin their debut, valuing the firm at about $5.48 billion,including debt. The company raised $460 million after itsinitial public offering of 23 million class A shares was pricedat $20 per share, above the expected range of $17-$19.

** ON SEMICONDUCTOR CORP, $11.2, -7.51 pct

Goldman Sachs downgraded the power management chip maker'sstock to "sell" from "neutral" and cut its price target to$10.50 from $12.50. The appreciation of the dollar will driveON's European and Asian competitors to be more aggressive onpricing, and data shows that pricing declines intensify when thedollar strengthens, Goldamn analysts wrote.

** TWITTER INC, $50.95, +1.74 pct

Jefferies & Co started coverage of the microblogging serviceprovider's stock with a "buy" rating and price target of $65.Twitter is "well positioned" to benefit from online videoadvertising and mobile tailwinds, Jefferies analysts said.

** PIER 1 IMPORTS INC, $13.16, -5.87 pct

Analysts at Morgan Stanley downgraded the furnitureretailer's stock to "underweight" from "equal-weight" and cuttheir target price to $11 from $13, saying sales at Pier 1'sretail business are expected to decline in the low single digitpercentage range, partly due to store volumes being cannibalizedby e-commerce sales.

** HONG KONG TELEVISION NETWORK LTD, $7.42, -22.47pct

The video production and distribution company said onTuesday that it had not agreed on a possible transaction withAsia Television Ltd (ATV). Seeking Alpha, citing media reports,also said on Tuesday that Hong Kong TV's Executive Chairman WongWai Kay was buying a controlling stake in nearly bankrupt rivalATV.

** ACHAOGEN INC, $7.81, -19.98 pct

The drug developer said it is planning an additionallate-stage trial of its lead drug to treat complicated urinarytract infections, and the U.S. FDA agreed to change the trialprotocol, which Achaogen believes will improve theslower-than-expected patient enrollment rate in the existingtrial. Needham & Co analysts, however, said the changes willmean a more modest initial sales ramp and cut the target priceon the stock by $6 to $15.

** TREVENA INC, $7.28, +11.66 pct

Wedbush Securities started covering the drug developer'sstock with an "outperform" rating and a $15 price target.Analysts said the company's drug for acute heart failure, whichis being tested in mid-stage studies, is "set up for success",and that Actavis Plc will exercise its option for theprogram if the study is successful.

** MICHAEL KORS HOLDINGS LTD, $64.3, -2.21 pct

Analysts at Piper Jaffray cut their rating on the luxuryaccessories retailer's stock to "neutral" from "overweight" andcut their price target to $70 from $89, saying they werecautious about North American same-store sales growth over next6-12 months. North America same-store sales growth slowed to 6percent in the three months ended Dec. 27, falling below 10 pctfor the first time.

** SOLAR3D INC, $5.3202, +6.40 pct

The solar cell developer reported a full-year adjustedprofit, compared with a loss a year earlier.

** FORD MOTOR CO, $15.86, -1.73 pct

** GENERAL MOTORS CO, $36.825, -1.80 pct

** FIAT CHRYSLER, $16.22, -0.55 pct

U.S. consumer demand for new vehicles began to thaw in Marchwith Detroit automakers reporting mixed sales results. FordMotor's U.S. sales fell 3.4 pecrent, while General Motorsreported a 2.4 pecrent fall, and Fiat Chrysler sales grew 2pecrent.

** EURONAV NV, $12.6, +4.48 pct

The tanker company proposed a gross dividend of 25 cents pershare in view of strong tanker markets. The company also plansto distribute at least 80 pct of its "annual net result" forfuture dividends as part of new dividend policy.

** EXCO RESOURCES INC, $2, +9.29 pct

The oil and gas producer named Chief Financial OfficerHarold Hickey chief executive, and said Bluescape Resources CoLLC, an investment firm focused on the oil and gas industry,would buy $10 million of EXCO's shares and an additional $40million in shares on the open market within one year fromclosing. EXCO and Bluescape will work on executing restructuringcommercial contracts and JVs, and increase focus on reducingcosts.

** ENERGY RECOVERY INC, $2.96, +14.29 pct

The energy recovery devices maker said it had received itslargest project to date in the oil and gas industry. SaudiAramco's gas processing plant will become the first to useEnergy Recovery's IsoGen system, a turbogenerator that recyclesotherwise wasted pressure energy and converts it into electricalpower.

** IMMUNE DESIGN CORP, $26.26, +24.40 pct

Analysts at Jefferies & Co upgraded the drug developer'sstock to "buy" after it reported positive data from early-stagestudies of its experimental cancer compounds. Immune Design onTuesday said results from three early studies showed that itstwo primary cancer drugs were safe and showed signs of efficacy.

** CAMPUS CREST COMMUNITIES INC, $6.46, -9.78 pct

The owner and manager of student housing properties said itdoes not anticipate declaring any dividend payments for 2015.The company also suspended the dividend payment on its series Acumulative redeemable preferred shares.

** NYMOX PHARMACEUTICAL CORP, $1.2899, +53.56 pct

The drug developer said it would undertake further analysesof its failed pivotal U.S. late-stage studies, including newlong-term data, of its drug, NX-1207. The company also said itexpects to provide new pivotal late-stage study results in thesecond-quarter or early in the third-quarter.

** WAL-MART STORES INC, $80.6, -2.01 pct

The world's largest retailer is looking at how it sourcesits products, especially considering falling commodity pricesglobally, in an effort to reduce its prices, the head of theretailer's U.S. division said on Wednesday. Speaking at abriefing for analysts and investors, Greg Foran said the gap inpricing between Wal-Mart and its competitors in some markets was"too small".

** COHERUS BIOSCIENCES INC, $27.67, -9.52 pct

The biotech company priced its offering of 4.1 millionshares at $29 each, a 5 pct discount to stock's Tuesday close.The upsized $120 million offering represents 12 percent of thecompany's outstanding shares as of Feb. 28.

** AMERICAN AIRLINES GROUP INC, $50.3101, -4.68 pct

** DELTA AIR LINES INC, $43, -4.36 pct

** UNITED CONTINENTAL HOLDINGS INC, $64.4, -4.24 pct

Analysts at Deutsche Bank cut ratings on airlines' stocks to"hold" from "buy", saying they expect disappointing earningsgrowth from international markets. The combination of a strongUS dollar, greater-than-expected capacity increases by non-USairlines, and decelerating global GDP growth are likely tofurther pressure Deutsche Bank's forecast (from internationalmarkets) for 2015, analysts write in a note.

** MACERICH CO, $79.63, -5.57 pct

** SIMON PROPERTY GROUP INC, $197.54, +0.97 pct

Simon Property Group scrapped its attempt to buy Macerichafter the smaller shopping mall owner rejected its sweetenedoffer of $23.2 billion including debt. Macerich Chief ExecutiveArthur Coppola said the company's board concluded that the offerdid not reflect the full value of the company.

** GLAXOSMITHKLINE PLC, $46.58, +0.93 pct

** MERCK & CO INC, $56.76, -1.25 pct

Cowen & Co analysts said the drugmaker's vaccine totreat shingles may be more effective than Merck's. Glaxo'svaccine HZ/su should be well positioned to capture market sharefrom Merck's Zostavax if final data from a late-stage studyshows HZ/su has better efficacy while treating older patients,analysts said.

** NUVASIVE INC, $45.15, -1.83 pct

The medical device maker said its chief executive of 16years Alex Lukianov had resigned after an independentinvestigation showed he had not complied with the medical devicemaker's expense reimbursement and personnel policies. Theamounts involved appeared immaterial to financial results, thecompany said. NuVasive has appointed board member Greg Lucier asinterim CEO.

** EVERYWARE GLOBAL INC, $0.223, -81.42 pct

The marketer of tabletop and food preparation products saidit expects to file for prepackaged bankruptcy that will give itssecured lenders control of the company after it emerges from thebankruptcy. EveryWare said it expects to file for a prepackagedChapter 11 bankruptcy in the U.S. Bankruptcy Court for theDistrict of Delaware and expects to emerge from bankruptcywithin 60-75 days.

** DYAX CORP, $25, +49.21 pct

The drug developer said its experimental drug, DX-2930, toprevent hereditary angioedema attacks, was found effective in anearly stage study. The drug was also assigned fast-track statusby the U.S. FDA. All seven analysts covering the stock raisedprice targets, saying the strong results show the drug couldeclipse the current standard-of-care preventive treatment forHAE.

** UTI WORLDWIDE INC, $10.3425, -15.91 pct

The logistics company reported a wider-than-expectedfourth-quarter loss, hurt by lower air and ocean freightforwarding yields and lower volumes in freight forwarding. Thecompany also cuts its 2016 adjusted EBITDA forecast to $125million-$150 million from $190 million-$210 million and saidrevenue would be hurt by the strengthening of the dollar. MorganStanley cuts price target by $2.50 to $10, now the lowest onWall Street.

** SYNNEX CORP, $72.95, -5.57 pct

The hardware distributor forecast second-quarter revenue andadjusted profit below analysts' average estimates, sayingrevenue is expected to be lowered by about $130 million due tothe stronger dollar. The company on Tuesday also reportedlower-than-expected first-quarter profit and revenue.

** SEARS HOLDINGS CORP, $42.88, +3.62 pct

The struggling retailer plans to raise more than $2.5billion from shareholders by offering rights to buy shares in areal estate investment trust that will hold some of its stores.The REIT, Seritage Growth Properties, will buy and lease backabout 254 Sears and Kmart stores, Sears said on Wednesday. Searsalso said it would sell 12 stores to a joint venture it wasforming with No.2 U.S. mall operator General Growth PropertiesInc, in which the companies would hold 50 percent each.

** VOLTARI CORP, $2.6701, +164.37 pct

Billionaire investor Carl Icahn raises his stake in thedigital advertising company to 52.3 percent. Icahn bought about4 million Voltari shares at $1.36 each via a rights offering.

** MYLAN NV, $58.4, -1.60 pct

** ABBOTT LABORATORIES, $45.71, -1.34 pct

The generic drug maker priced an offering of 35 millionshares at $58.35 per share, a discount of about 2 percent to thestock's Tuesday close. All shares in the offering are to be soldby Abbott Laboratories for net proceeds of about $1.99 billion.

** CARPENTER TECHNOLOGY CORP, $36.14, -7.05 pct

The alloys maker said on Tuesday that it will cut about 10percent of its salaried workforce, or 200 jobs, to reduce costsamid weak oil and gas prices. The company will also cut about 60outsourced positions.

** SAREPTA THERAPEUTICS INC, $14.15, +6.55 pct

The drug developer appointed Chief Medical Officer EdwardKaye as interim CEO, replacing Christopher Garabedian, whoresigned. Sarepta is also expected to meet with the FDA over thecoming weeks to finalize an application to market its lead drug,eteplirsen, which is designed to attack the underlying cause ofDuchenne muscular dystrophy (DMD), a progressive muscle wastingdisorder.

** CYTOSORBENTS CORP, $10.4201, -21.00 pct

The medical device maker said it expects first-quarter salesto be slightly lower than they were in the fourth-quarter asrestructuring of its direct sales force created a significantgap in sales coverage and resulted in lower direct sales.

** CHESAPEAKE ENERGY CORP, $14.44, +1.98 pct

The oil and gas producer's Chairman Dunham Archie bought 1million shares at $13.98 per share on March 27, according to aregulatory filing on Tuesday. The purchase price represents a1.3 percent discount to the stock's Tuesday close. After thepurchase, Archie holds 2.6 million shares of the company. (Compiled by Ramkumar Iyer in Bengaluru; Editing by SimonJennings)

More News
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.